Employers are spending more on GLP-1 drugs, but the ROI is already here
Briefly

Employers are spending more on GLP-1 drugs, but the ROI is already here
"GLP-1 treatments, while initially expensive, lead to significant long-term savings in employee medical costs, particularly for conditions like obesity and cardiovascular health."
"The analysis highlights that GLP-1 drug users experienced a drastic reduction in overall medical costs and fewer hospitalizations related to cardiac incidents."
A new Aon report analyzed health insurance claims for over 50 million U.S. residents, revealing that while GLP-1 weight loss medications can be costly upfront, they result in significant long-term savings on medical expenses for both employers and employees. The study tracked data from 2022 to 2024, noting that costs for GLP-1 users decreased substantially after the initial spike. Additionally, users experienced a notable reduction in cardiovascular incidents and other health issues, affirming the potential benefits of these treatments in managing chronic diseases and reducing overall healthcare costs.
Read at Fast Company
Unable to calculate read time
[
|
]